Business Context and Reporting Period
This Form 8-K is a current report filed by Halozyme Therapeutics, Inc. on August 14, 2026. The filing discloses a corporate governance event regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the election of a new director:
- Event: Dannielle Appelhans was elected to the Board of Directors on August 14, 2026.
- Term: Her term ends at the Company's annual meeting of stockholders in 2028.
- Committee Assignments: She was not initially assigned to any Board committee.
Guidance, Outlook, and Compensation
There is no guidance, outlook, or management commentary regarding business operations in this filing. Regarding compensation:
- Ms. Appelhans will receive compensation under the standard non-employee director program.
- Compensation components include cash retainers for Board and committee service, restricted stock, and stock option awards.
- The program details were previously described in the proxy statement for the 2026 Annual Meeting of Stockholders held on May 5, 2026.
- The Company states there are no related person transactions or special arrangements regarding her election.
Investor Verification Checklist
- Verify the biographical background and qualifications of Dannielle Appelhans.
- Review the 2026 Proxy Statement to confirm the specific dollar amounts and equity grant details of the director compensation program.
- Monitor future filings for any committee assignments given to the new director.